GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poseida Therapeutics Inc (NAS:PSTX) » Definitions » FCF Yield %

Poseida Therapeutics (Poseida Therapeutics) FCF Yield % : -46.34 (As of Apr. 29, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Poseida Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Poseida Therapeutics's Trailing 12-Month Free Cash Flow is $-95.23 Mil, and Market Cap is $205.52 Mil. Therefore, Poseida Therapeutics's FCF Yield % for today is -46.34%.

The historical rank and industry rank for Poseida Therapeutics's FCF Yield % or its related term are showing as below:

PSTX' s FCF Yield % Range Over the Past 10 Years
Min: -93.62   Med: -25.52   Max: -4.44
Current: -46.34


During the past 7 years, the highest FCF Yield % of Poseida Therapeutics was -4.44%. The lowest was -93.62%. And the median was -25.52%.

PSTX's FCF Yield % is ranked worse than
73.53% of 1549 companies
in the Biotechnology industry
Industry Median: -15.5 vs PSTX: -46.34

Poseida Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -116.24%.


Poseida Therapeutics FCF Yield % Historical Data

The historical data trend for Poseida Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poseida Therapeutics FCF Yield % Chart

Poseida Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial - -19.19 -24.70 -6.74 -29.64

Poseida Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.88 -58.06 -90.23 12.48 -36.16

Competitive Comparison of Poseida Therapeutics's FCF Yield %

For the Biotechnology subindustry, Poseida Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Poseida Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poseida Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Poseida Therapeutics's FCF Yield % falls into.



Poseida Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Poseida Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-95.233 / 321.338976
=-29.64%

Poseida Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-29.053 * 4 / 321.338976
=-36.16%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Poseida Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Poseida Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Poseida Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Poseida Therapeutics (Poseida Therapeutics) Business Description

Traded in Other Exchanges
Address
9390 Towne Centre Drive, Suite 200, San Diego, CA, USA, 92121
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
Executives
John P. Schmid director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Luke Corning director 614 DAVIS STREET, EVANSTON IL 60201
Marcea Bland Lloyd director 9360 TOWNE CENTRE DRIVE, SUITE 110, SAN DIEGO CA 92121
Charles M Baum director C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Cynthia Collins director 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Rafael Amado director 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Kristin Yarema officer: President, Cell Therapy C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080
Malin Life Sciences Holdings Ltd 10 percent owner 2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ----
Eric Ostertag director, 10 percent owner, officer: Chief Executive Officer C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121
Kerry D. Ingalls officer: Chief Operating Officer C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Brent Warner officer: President, Gene Therapy C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Matthew A. Spear officer: Chief Medical Officer C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121
Harry J Leonhardt officer: GC & Chief Compliance Officer C/O HALOZYME THERAPEUTICS, INC., 11388 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121
David Hirsch director C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Sean Murphy director, 10 percent owner C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703